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NP systems for drug delivery applications. (Adapted with permission from 119 © 2005 Elsevier; and from 
120 © 2005 PharmaVentures Ltd.)
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Nanostructures
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https://scholar.google.com/
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Research Of Liposome Trend
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Research Of NanoLiposome Trend
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Timeline of the development of nanomedicines(15)
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Liposomes were first described by British haematologist Alec D Bangham in 1961 , 
at the Babraham Institute, in Cambridge.[1]
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https://www.researchgate.net/profile/Abdallah_Laouini
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Bridging small interfering RNA with giant therapeutic outcomes using nanometric liposomes Author links open overlay panel YuvrajSingha SandeepTomar(2015)
Liposome’s formation
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https://www.youtube.com/results?search_query=Liposome_+A+Technological+Marvel+Module2.avi
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https://www.youtube.com/results?search_query=Liposome_+A+Technological+Marvel+Module2.avi
Why do we use of liposomes?(1)
 Manufactured size controlled
 High drug/lipid ratios 
 Long-circulating (stealth coating)
 Mimic the properties of biological membranes[28]
 Target-specific delivery
 Enhanced intracellular penetration
 Contrast enhancement for image-guided therapy
14
Classification(3)
Based on : 
 structural parameters
 method of preparation
 composition and applications
15
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Based on structural parameters(3)
• : 
17
MLV
Multi lamellar Vesicles
200nm -3𝝁m
OLV
Oligo lamellar Vesicles
ULV
Uni Lamellar Vesicles
20-400 nm
SUV
(Small)
MUL
(Medium)
LUV
(Large)
GUV
(Gaint)
1𝝁𝒎
On the basis of their size and number of bilayers, liposomes can 
also be classified into one of three categories
18
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Based on method of preparation
20
DRV
Dehydration and 
Rehydration
REV
SULs/OLVs made 
by reverse
phase 
evaporation 
method
MLV-REV
MLV made by 
reverse phase
evaporation 
method
VET 
Vesicles prepared 
by Extrusion
Technique
FATMLV
Frozen and 
thawed MLV
SPLV
Stable 
plurilamellar
vesicles
•A Cheap and Convenient Method of Liposome Preparation Using Glass Beads as a Source of Shear Force , Aoke Wang ,Aftab Ahmad, Sadeeq Ullah, Li Cheng,Lin Ke , Qipeng Yuan  
(2017)
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Methode Of liposom Prepration
22
Passive loading Technique
(during)
Active Loading Technique
(after)
Mechanical Dispersion 
Methodes
Solvent Dispersion 
Methodes
Detergent Removal 
Methodes
 Lipid film hydration by 
hand shaking non-hand 
shaking or freeze drying(t-
butanol)
 Micro emulsification 
 Sonocation
 French pressure cell
 Membrane extrusion
 Dried reconstituted 
vesicles
 Freeze thawed liposomes
 Ethanol injection 
 Ether injection
 Double emulsion 
vesicles
 Reverse phase 
evaporation vesicles
 Stable plurilamellar
vesicles
 Detergent (cholate
,alkylglycoside,Trito
n x-100) removal 
from mixed 
micellesby: 
 Dialysis
 Column 
chromatogeraphy
 Dilution 
 Reconstituted sandal 
virus enveloped 
vesicles 
the preparation process of co-encapsulated Nano-liposomes
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https://www.researchgate.net/Schematic-model-for-the-preparation-process-of-co-encapsulated-nano-liposomes_fig1_305375457 [accessed 5 Jul, 2018]
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https://www.youtube.com/results?search_query=Liposome+Basics-Part+two
25https://www.youtube.com/results?search_query=Liposome+Basics-Part+two
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Physical Characterization
Parameter Characterization method
Vesicle shape and surface
morphology
Transmission Electron Microscopy,
Freeze-fracture electron microscopy
Mean vesicle size and size
Distribution
Dynamic light scattering, zetasizer,
Photon correlation spectroscopy, laser light
scattering, gel permeation and gel exclusion
Surface charge Free-flow electrophoresis
Electrical surface potential and
surface pH
Zeta potential measurements & pH sensitive 
probes
Percent of free drug/
percent capture
Mini column centrifugation, ion-exchange
Chromatography , radiolabelling
Drug release Diffusion cell/ dialysis
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Chemical Characterization
Parameter Characterization method
Phospholipid concentration Barlett assay, stewart assay, HPLC
Cholesterol concentration Cholesterol oxidase assay and HPLC
Phopholipid peroxidation UV absorbance, Iodometric and GLC
Phospholipid hydrolysis,
Cholesterol auto-oxidation
HPLC and TLC
Osmolarity Osmometer
28
Biological Characterization
Parameter Characterization method
Sterility Aerobic or anaerobic cultures
Pyrogenicity Limulus Amebocyte Lysate (LAL) test
Animal toxicity Monitoring survival rates, histology and 
pathology
29
Flow Cytometry with Fluorescent Dyes  
fast and reliable method 
for liposomes assessment [5] 
30
Measurement particle size and drug content (36)
31
32
Baesd on Composition & Application
33
CL
(conventional 
liposomes)
Fusogenic
liposomes
PH sensitive 
liposomes
Nuetral/negatively charged phospholipids 
& cholesterol
RSVE-Reconstituted Sendai Virus 
Envelopes
Using phospholipids such as PE or DOPE 
with OA
34
Catinoic &Anionic 
& Neutral 
Liposomes
Long 
Circulatory(stealt) 
liposomes (LCL)
Immuno -
liposomes
Catinoic lipids with DOPE 
High TC made using cholesterol & 
5-10% PEG –DSPE or GM1
With attached monoclonal 
antibody
Drug delivery by liposomes (14)
35
Types Of Liposomal Drug Delivery Systems[4]
36
37
Primary Amines by Glutaraldehyde
Classical methods for coupling ligands(17)
carbonyl-amine
amide bond 
disulfide bond
thioester bond 
hydrazone bond 
Coupling ligands red stars
PEG (polyethylene glycol )(4)
• The Hydrophilic Polymer ,Obtaining Sterically-stabilized 
Liposomes
• Reduce Invivo Opsonization
• Reduce Rapid Recognition RES .
• Half-lives  (2 - 24 h) In Rodents , (45 h) In Humans
• Reduced EPR Effects
38
(ABC) Phenomenon[4]
• Accelerated Blood Clearance
• Repeated injection of PEGylated liposomes (long circulating properties ) 
• Affected by :
a. Lipid dose
b. PEG surface density
c. The interval between the first and consecutive injections 
39
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https://www.youtube.com/watch?v=vUqwIL5lgS8
Cationic liposomes
• In Gene Delivery : 
 cancer Treatment (RGD -cationic for angiogenes inhibition)(9)
 Designed Anti oxidant Lipid (Treating ROS Related Diseases )(10)
 With Poly hydroxyl (combine with DNA and lipoplexes(A complex of 
DNA and liposome )) (11)
• In Gene Therapy :
 AS Non Viral Vector : (CRISPR/Cas9 gene-editing systems )[12]
 Induced cell Necrosis[18]
 As Carrier For plasmid DNA , siRNA and miRNA [12]
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Strategies for overcoming drug resistance using modified liposomes[18]
Strategy Proposed mechanism
Anionic liposomes
Triggered release • Modified liposomes can increase 
and optimize drug release in target tissue dependent
• Anionic lipids may inhibit PGP
• Possible internalization
Other inhibitory lipids • Certain phospholipids may inhibit PGP
Thermosensitive liposomes • Modified liposomes can release drug upon 
hyperthermia treatment
Triggered release • Modified liposomes can increase and optimize drug 
release in target tissue dependent on pH or other 
triggers
Combining liposomes and
resistance inhibitors
• Liposomal chemotherapeutic may be better than 
free drug in combination with
resistance inhibitors
• Liposome delivery of resistance inhibitors may 
increase therapeutic index
Delivery of hydrophobic drug analogs • Liposomes can deliver poorly soluble drugs that are 
not substrates for PGP
Gene therapy approaches • Non-viral delivery of nucleic acid-based constructs 
to tumor cells to reverse,
circumvent, or exploit drug resistance
• Non-viral delivery of resistance genes to normal 
tissues to protect them from chemotherapy
(“chemoprotection”)
47
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Liposome-based drug co-delivery systems in cancer cells Sepideh Zununi Vahed a, Roya Salehi a,b, Soodabeh Davaran a,b, Simin Sharifi(2017)
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Application of liposom
 treatment of heavy metal poisoning
Enzyme Replacement
Diagnostic imaging of tumors  
Cosmetics 
 Study of membranes
Drug delivery
Bioreactor
50
Medical Application of liposom
 Pain Control
 Rapid Patient Recovery
 Increased Patient Comfort
 Treatment Costs Reduction
 Shortens Length Of Hospitalization
51
Application of Nanoliposomes in Anesthesia (22) 
Bioreactors 
• Liposome used as Microreactors (41)
• Application in biotechnology & medicine.
52
bioreactor\am-2013-05992t_0012.gif
53Mechanosensitive Liposomes as Artificial Chaperones for Shear-Driven Acceleration of Enzyme-Catalyzed Reaction Tomotaka Natsume and Makoto Yoshimoto*(2014)
54
A liposome-actuated enzyme system and its capability as a self-biomineralized silica nanoreactor† S. Municoy and M. G. Bellino(2017)  * 
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Characterization of in-liposome protein synthesis using an FACS (37)
56
Liposomes Application as Drug Carrier
• Enzymes
• Anti Cancer Drugs
• Anti Fungal Drugs
• Anti Viral Drugs
• Anti Bacterial Drugs
• Anti parasite Drugs
• Different Types Of Nucleic Acid inTransgenesis
• AS Adjuant
57
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(1)
Mode of action of liposomal-cell interactions[14] 
I. Lipases enzyme degrades the liposomes membrane
II. Fusion with the plasma membrane of the target cells
III. A kind of receptor-mediated endocytosis
 level of liposome–cell interaction is strongly : 
I. nature of the charge
II. density of the charge
59
Mode of action of liposomal drug interactions[14]
• Nature Of The Lipid Bilayer
• Size Of The Drug Molecules
• Drug Interactions With The Lipid Membrane
• polarity and partition coefficient
I. Hydrophobic drugs resides in the acyl hydro carbon chain of 
the liposome 
II. Polar localize in the aqueous core (very close to the polar 
head groups)
60
The use of liposomes in veterinary vaccine formulations [33]
Liposome use in the delivery of drugs in the veterinary field
Encapsulated agent Drug activity 
Proteins or whole cell extracts Antimicrobial 
Plasmids encoding vaccine antigens Antitumoral
Lipid Immunosuppresor
Adjuvants and immunomodulators Analgesic 
Anti-inflammatory 
Diagnostic imaging 
61
AS vaccine adjuvants including bilayer rigidity , vesicle size vesicles , biodistribution , 
antigen location and vesicle charge [34]
62
FDA approved liposomal-based therapeutics[4]
Drug Disease Type Of Liposomal-
based Delivery System 
Verteporfin Molecular Degeneration Cationic 
Vincristine Non-hodgkin Lymphoma Conventional 
Amphotericin B Anti-fungal Prophylaxis Conventional 
Cytarabine Or Cytosine 
Arabinoside
Neoplastic Meningitis And Lymphomatous
Meningitis 
Conventional
Morphine Sulfate Pain Management Conventional
Doxorubicin Leukemia, Breast Cancer, Bone Cancer, Lung 
Cancer, Brain Cancer 
Pegylated
Doxorubicin And 
Bortezomib
Relapsed Or Refractory Multiple Myeloma Pegylated
Daunorubicin Leukemia and solid tumors Conventional 
63
Phase I trial liposomal-based therapeutics[4] 
Drug Disease Type Of Liposomal-based 
Delivery System 
Sirna Ovarian Cancer DOPC Neutral Liposomes 
Mitoxantrone LEM-ETU
Acute Myeloid Leukemia, 
Multiple Sclerosis, And Prostate 
Cancer 
Cationic 
Vinorelbine Newly Diagnosed Or Relapsed 
Solid Tumors 
Conventional 
Thermosensitive
Doxorubicin 
Chest Wall Recurrences Of Breast 
Cancer 
Pegylated
Irinotecan Advanced Refractory Solid 
Tumors And Colorectal
Pegylated
Camptothecin Analog Ovarian Cancer Pegylated
64
Phase II trial liposomal-based therapeutics[4] 
Drug Disease Type Of Liposomal-
based Delivery System 
Paclitaxel Endotag-1 Advanced Triple-negative Breast Cancer Cationic 
Paclitaxel Endotag-1 Pancreatic Cancer Cationic 
Tretinoin Acute Promyelocytic Leukemia And Hormone-
refractory Prostate Cancer 
Conventional 
65
Thermosensitive doxorubicin (Liver tumors) ,Phase III PEGylated
Phase I/II trial liposomal-based therapeutics[4] 
Drug Disease Type Of Liposomal-based 
Delivery System 
Paclitaxel LEP-ETU Advanced Triple-negative Breast 
Cancer 
Sirna
Amikacin Lung Infection Conventional 
Irinotecan SN-38 Cancer Metastatic Colorectal Conventional 
Annamycin Acute Lymphoblastic Leukemia Conventiona
Lurtotecan Ovarian Cancer, Head, And Neck 
Cancer 
Conventional 
Topotecan Advanced Solid Tumors Conventional
Nystatin Fungal Infections Conventional 
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Liposomes present under different phases of clinical trial investigation(1)
68
Advantage & Disadvantage Of Liposome Technology
Liposomal Porphyrinoid
• Porphyrin photosensitizers are mostly used components in photodynamic ther-
apy (PDT). [23]
• liposomes as delivery for porphyrinoids overcome many drawbacks of 
conventional photosensitizers.[24]
• further development is necessary for metallo-porphyrin doped liposomes to 
become general delivery mechanisms[25]
• the liposomal structures for delivery of photosensitizers, a novel class of     
phototransducing liposomes called"porphysomes".[26]
• The delivery of photosensitizers to the tumor cells using liposome vehicles can 
help to overcome this problem. [23]
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ADVANTAGES(30)
 passive targeting to tumor tissues.
 Site avoidance effect ( avoide non-target tissues).
 Increased efficacy and therapeutic index.
 Reduces toxicity or Non-toxic.
 ability for self-assembly
 Biodegradable.
 Non-immunogenic.
 Protection of sensitive drug molecules.
 Enhance drug solubilisation ( Amphoterecin, Cyclosporins).
 Improved pharmacokinetic effects.
70
DISADVANTAGES
 Production cost is high .
Batch to batch variation
Leakage & fusion of encapsulated molecules.
 Some times phospholipids undergoes. oxidation & 
hydrolysis like reaction.
 Short half-life
Low solubility
71
Advantages  and Disadvantages[29]
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